Answers are grounded in this paper and cite their sources.
SH2B3 is located on chromosome 12q24.12 and encodes the SH2 domain-containing lymphocyte adaptor protein (lymphoid nodal cell kinase; Lnk) that regulates cytokine signaling, including those mediated by wild-type or mutant MPL and JAK2 [1-5]. In other words, Lnk also functions as a negative regulator of myeloproliferation [6]. In 2010, we described the presence of SH2B3 exon 2 mutations (E208X and A215V) in 2 of 8 patients with idiopathic erythrocytosis [7]. In a subsequent report, we screened 61 patients with blast phase myeloproliferative neoplasms (MPN), including chronic phase samples from some of the patients, and identified 9 novel SH2B3 exon 2 mutations (E208-D234) in 6 blast phase and 2 chronic phase MPN samples [8]. Several other reports of SH2B3 mutations in idiopathic erythrocytosis [9], sporadic [9] or familial MPN [10], juvenile myelomonocytic leukemia (JMML) [11] and other [12] myeloid neoplasms [11], and acute lymphoblastic leukemia [13] have since been described. The objective of the current study was to outline the morphologic spectrum of pathogenic SH2B3 variants during a myeloid neoplasm-focused next-generation sequencing (NGS) testing at the Mayo Clinic and describe the associated morphologic category-specified clinical and genotype correlates. The study was conducted under Mayo Clinic Institutional Review Board (IRB)-approved protocols, and pathology diagnoses were rendered by board-certified hematopathologists following the 2017 WHO/2022 ICC criteria [14, 15]. Carefully curated institutional cohorts were used to estimate disease-specific incidence rates, genotype correlates, and prognostic relevance. Cytogenetic results were reported according to the International System for Human Cytogenetic Nomenclature [16]. Laboratory methods used in NGS have previously been published [17]. All patients were followed until death or last follow-up, as assessed by medical records or through direct contact with patients or their physicians. Treatment received, often at the discretion of the treating physician, at any time during the disease course, was reviewed and documented. Chi-square and correlation analyses were systematically used to compare the clinical and laboratory parameters. The Kaplan–Meier method was used to construct time-to-event curves, which were compared by the log-rank test. Multivariable logistic regression analysis was used to adjust for confounding variables. A p value of ≤ 0.05 was considered significant. Statistical analyses were conducted using JMP Pro 18.0.1 software (SAS Institute, Cary, NC, USA). An enterprise-wide search involving 13,341 Mayo Clinic cases who underwent NGS studies for suspected or diagnosed hematologic malignancy (November 2018 to July 2025) identified a total of 65 (0.5%) patients (including 58 with myeloid neoplasms; Table 1) with pathogenic or likely-pathogenic SH2B3 mutations. Morphologic diagnoses included acute myeloid leukemia (AML; N = 19), MPN (N = 14), myelodysplastic syndromes (MDS; N = 12), chronic myelomonocytic leukemia (CMML; N = 9), MDS/MPN (N = 3), systemic mastocytosis (SM; N = 1), clonal cytopenia of undetermined significance (CCUS; N = 3), clonal hematopoiesis of indeterminate potential (CHIP; N = 1), non-Hodgkins lymphoma (NHL; N = 1), chronic lymphocytic leukemia (CLL; N = 1), and monoclonal gammopathy of undetermined significance (MGUS; N = 1). Among the 19 cases with AML, 6 were primary, 2 were therapy-related, and 11 were secondary; the latter included post-CMML (N = 4), post-MDS (N = 3), post-MPN (N = 3), and post-SM (N = 1) AML. Among the 14 MPN cases, 8 had primary myelofibrosis (PMF), 4 had essential thrombocythemia (ET), and 2 had polycythemia vera (PV). The three MDS/MPN cases included one patient each with MDS/MPN with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T), MDS/MPN with ring sideroblasts and thrombocytosis, not otherwise specified (MDS/MPN-RS-T, NOS), and MDS/MPN, NOS. Among the 58 SH2B3-mutated patients with myeloid neoplasm, 51 harbored one, 6 harbored two, and 1 harbored five distinct SH2B3 mutations, constituting a total of 68 SH2B3 variants (Table 1). They included 44 frameshift, 15 nonsense, 2 missense, and 7 other mutation types with variant allele frequency (VAF) median and range values outlined in Table 1 with additional details provided in Table S1. Co-mutations were documented in 53 (91.4%) of the 58 SH2B3-mutated patients with myeloid neoplasms while 5 carried only SH2B3 mutations with VAF of 76% (PMF with normal karyotype), 49% (ET with normal karyotype), 36% [MDS with del(20q)], 32% [MDS with del(20q)], and 18% (ET with normal karyotype). The most frequently co-mutated genes included TET2 (N = 23; 15% of all co-mutations; 40% of patients with myeloid neoplasms), SRSF2 (N = 21; 14%; 36%), ASXL1 (N = 17; 11%; 29%), JAK2 (N = 14; 9%; 24%), and RUNX1 (N = 11; 7%; 19%) [Table 1]. Table 2 outlines age and sex distributions and co-mutation patterns in SH2B3-mutated AML (N = 19) versus MPN (N = 14) versus MDS (N = 12) versus CMML (N = 9). Among chronic myeloid neoplasms, co-mutations involving TET2 (78%) and SRSF2 (78%) were significantly more likely to be seen with CMML while those involving JAK2 (50%) and CALR (21%) were mostly seen with MPN (Table 2). TP53 co-mutations were exclusively seen in AML (21%; p = 0.02) where higher frequencies were also noted for co-mutations involving TET2 (32%), SRSF2 (42%), ASXL1 (37%), JAK2 (26%), and RUNX1 (21%). Cytogenetic studies revealed an abnormal karyotype other than loss of the Y chromosome in 24 (41%) of the 58 patients with myeloid neoplasms including 13 (68%) of 19 in AML, 6 (43%) of 14 in MPN, 3 (25%) of 12 in MDS, and 1 (11%) of 9 in CMML. Specific cytogenetic abnormalities included trisomy 8, chromosome 7 abnormalities, and complex karyotype seen in all morphological categories. Disease-specific incidence rates were estimated in the context of carefully curated patient cohorts and included 0.8% (4/518) in AML, 1.2% (7/600) in CMML, 1.5% (9/614) in PMF, 2.5% (8/318) in PV, 0.3% (1/401) in ET, and 2.2% (2/91) in MPN-BP; a similar cohort in MDS was not available for analysis. Of note, the AML and MPN-BP cohorts constituted mostly unfit patients receiving upfront treatment with venetoclax and hypomethylating agent (Ven-HMA) or CPX-351. In AML, presence of SH2B3 mutations was significantly correlated with female sex (p < 0.01; all 4 cases were females) and BCOR mutation (p = 0.03). Interestingly, SH2B3-mutated AML patients (N = 4) were more likely to achieve CR (100%) compared to those that were SH2B3 wild-type (59%; p = 0.04) but overall survival was not impacted (p = 0.88). In CMML, SH2B3 mutation clustered with PHF6 mutation (57% vs. 7%; p < 0.01) but did not affect survival (p = 0.15); of note, SH2B3 mutations in CMML were not seen in the presence of circulating blasts ≥ 2% (p = 0.046) but no association was apparent in regard to myelodysplastic versus proliferative disease (p = 0.5), CMML-1 versus CMML-2 (p = 0.6), or severity of anemia (p = 0.4). In PMF, SH2B3 mutation correlated with marked leukocytosis (p = 0.03) without independent impact on overall (p = 0.13) or leukemia-free (p = 0.43) survival. In PV, SH2B3 mutation clustered with SETBP1 mutation (p < 0.01) but did not appear to impact overall, leukemia-free, or thrombosis-free survival. The current study provides general information on the prevalence and morphologic spectrum of SH2B3 mutations in myeloid malignancies and suggests a higher frequency in PV (2.5%), compared to ET (0.3%), and similar frequencies between PMF (1.5%) and CMML (1.2%). It should be noted that the observed incidence rates in AML and MPN-BP, as well as their co-mutation patterns, are confounded by heterogeneity in the type of antecedent myeloid neoplasms. Furthermore, the relatively small number of informative cases within each specific morphologic category undermines the significance of observed associations regarding mutations or clinical features. Nevertheless, the observations from the current study do not suggest a significant survival impact from SH2B3 mutations in either acute or chronic myeloid neoplasms. On the other hand, loss of the JAK–STAT signal regulatory function of mutant SH2B3 (Lnk) might contribute to phenotype modification in MPN, including an erythropoietic effect, while loss of function in constraining Bcl-xL expression by mutant stem cells might unveil therapeutic vulnerability to pro-survival protein-targeted therapy [18, 19]. Whether or not such a scenario contributes to impact on treatment response to specific agents, as suggested by the current study, requires additional studies with a substantially larger number of informative cases. A.T., M.Y., S.J.W., S.F., and Y.A.B. participated in study design and data collection and analysis. A.T. wrote the paper. A.T., A.P., and N.G. participated in patient care. K.K.R., R.H., and C.J.Z.M. provided hemato-pathology expertise. All authors reviewed and approved the manuscript. The authors have nothing to report. The authors declare no conflicts of interest. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Table S1: Comprehensive classification of pathogenic SH2B3 mutations (N = 68) in patients with myeloid malignancies (N = 58). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Tefferi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: